Lancet HIV

Journal

Publication Venue For

  • Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial.  9:e332-e340. 2022
  • Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.  8:e679-e689. 2021
  • Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study.  8:e495-e501. 2021
  • Variations in the characteristics and outcomes of children living with HIV following universal ART in sub-Saharan Africa (2006–17): a retrospective cohort study.  8:e353-e362. 2021
  • Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.  7:e688-e698. 2020
  • Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework.  7:e582-e592. 2020
  • Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: A systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017.  6:e831-e859. 2019
  • Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.  6:e498-e508. 2019
  • Safer conception care to eliminate transmission of HIV.  6:e413-e414. 2019
  • Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study.  6:e240-e249. 2019
  • Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies.  6:e93-e104. 2019
  • Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.  5:e715-e722. 2018
  • Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.  4:e486-e494. 2017
  • Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.  4:e349-e356. 2017
  • Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.  4:e251-e259. 2017
  • Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study.  4:e449-e456. 2017
  • Erratum: Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: The Global Burden of Disease Study 2015 (The Lancet HIV (2016) 3 (e361-e387) PII: S235230181630087X DOI: 10.1016/S2352-3018(16)30087-X).  3:e408. 2016
  • Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015.  3:e361-e387. 2016
  • Tuberculosis-related mortality in people living with HIV in Europe and Latin America: An international cohort study.  3:e120-e131. 2016
  • Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk - Authors' reply..  2:e366-e367. 2015
  • Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial.  2:e319-e327. 2015
  • Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: A prospective cohort study.  2:e279-e287. 2015

    • Electronic International Standard Serial Number (eissn)

  • 2352-3018